Pharmafile Logo

Healthy Community Project

Sanofi continues pharma’s trend of ditching the corporate blog

Will integrate Speaking of Sanofi content into its main US website

- PMLiVE

FDA panel backs CV claims for Novo Nordisk’s Victoza

LEADER trial shows the diabetes treatment reduces risk of cardiovascular death by 13%

- PMLiVE

Trial of J&J’s canagliflozin boosts SGLT2 cardiovascular credentials

Invokana cuts risk of heart failure hospitalisation by a third

- PMLiVE

Novo says real-world data backs its insulin switching

EU-TREAT study shows Tresiba improved blood glucose control

Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report

Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

Research Partnership

- PMLiVE

Novo seeks to strengthen Tresiba label in US

Studies find insulin degludec advantage over insulin glargine

Sanofi reception

Sanofi/Regeneron’s Sarilumab cleared by FDA on second attempt

IL-6 inhibitor to treat adult RA patients

- PMLiVE

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Panel recommends insulin Lispro Sanofi to treat diabetes

Sanofi targets patient literacy in clinical trials drive

Unveils new online resources for those in the US

Sanofi reception

Sanofi agrees €250m diabetes deal with AI firm Exscientia

The French pharma giant will pay royalties and contribute research funding

Eli Lilly HQ

Surging Trulicity takes sting out of Lilly’s arthritis setback

First quarter sales of the diabetes treatment were up by 160%, exceeding analysts predictions

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links